Private Trust Co. NA Sells 13,434 Shares of AstraZeneca PLC (NASDAQ:AZN)

Private Trust Co. NA cut its position in AstraZeneca PLC (NASDAQ:AZNGet Rating) by 43.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,364 shares of the company’s stock after selling 13,434 shares during the quarter. Private Trust Co. NA’s holdings in AstraZeneca were worth $1,152,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Capital International Investors lifted its position in shares of AstraZeneca by 1.6% during the 4th quarter. Capital International Investors now owns 35,388,789 shares of the company’s stock valued at $2,062,518,000 after acquiring an additional 555,607 shares during the period. Fisher Asset Management LLC lifted its position in shares of AstraZeneca by 2.7% during the 4th quarter. Fisher Asset Management LLC now owns 20,109,886 shares of the company’s stock valued at $1,171,401,000 after acquiring an additional 520,259 shares during the period. GQG Partners LLC raised its holdings in shares of AstraZeneca by 5.3% during the 4th quarter. GQG Partners LLC now owns 19,453,752 shares of the company’s stock worth $1,132,984,000 after buying an additional 973,398 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of AstraZeneca by 1.8% during the 4th quarter. Bank of America Corp DE now owns 10,609,822 shares of the company’s stock worth $618,022,000 after buying an additional 184,411 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of AstraZeneca during the 4th quarter worth $542,230,000. Institutional investors and hedge funds own 20.46% of the company’s stock.

A number of equities analysts have issued reports on AZN shares. Stifel Nicolaus started coverage on AstraZeneca in a report on Monday, February 28th. They issued a “buy” rating for the company. Barclays upped their target price on AstraZeneca from £115 ($140.86) to £120 ($146.99) in a report on Thursday, April 14th. Danske started coverage on AstraZeneca in a report on Tuesday, May 24th. They issued a “buy” rating for the company. UBS Group cut AstraZeneca from a “buy” rating to a “neutral” rating in a report on Tuesday, June 14th. Finally, Kepler Capital Markets lowered AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8,246.29.

Shares of NASDAQ:AZN opened at $63.55 on Thursday. The business’s 50 day simple moving average is $64.96 and its two-hundred day simple moving average is $61.80. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 0.77. AstraZeneca PLC has a 52-week low of $53.63 and a 52-week high of $71.70.

AstraZeneca (NASDAQ:AZNGet Rating) last announced its quarterly earnings results on Friday, April 29th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.09. The business had revenue of $11.39 billion for the quarter, compared to analyst estimates of $10.96 billion. AstraZeneca had a positive return on equity of 25.35% and a negative net margin of 2.56%. The company’s quarterly revenue was up 55.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.81 earnings per share. On average, research analysts expect that AstraZeneca PLC will post 3.3 earnings per share for the current fiscal year.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Want More Great Investing Ideas?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.